David M. Swoboda, MD

Panelists discuss the immune profiles of responders vs non-responders to pelabresib in myeloproliferative neoplasms (MPNs).

Panelists discuss disease-modifying biomarker data from the MANIFEST-2 study investigating pelabresib in myelofibrosis.

Panelists discuss the safety profile of the pelabresib and ruxolitinib combination in myelofibrosis.

Panelists discuss approved and emerging therapies for myelofibrosis, focusing on how these treatments aim to modify the disease and improve patient outcomes.

Panelists discuss the MANIFEST-2 trial of pelabresib in myelofibrosis, focusing on its mechanism of action (MOA), study design, and impact on spleen volume reduction.

Panelists discuss how Janus kinase (JAK) inhibitors, including ruxolitinib, fedratinib, pacritinib, and momelotinib, as well as investigational agents like pelabresib and navitoclax, target the dysregulated JAK-STAT pathway to manage symptoms and potentially modify disease progression in myelofibrosis.

Panelists discuss how myelofibrosis management involves a combination of medications, supportive care, and potentially stem cell transplantation to alleviate symptoms, control disease progression, and improve quality of life.